根据最新提交至美国证券交易委员会(SEC)的文件,Mira Pharma旗下研究性药物Ketamir-2在一期临床试验中展现出良好的安全性与耐受性。该阶段试验结果显示,未出现任何严重不良事件或剂量限制性毒性,为后续临床开发奠定了重要基础。
根据最新提交至美国证券交易委员会(SEC)的文件,Mira Pharma旗下研究性药物Ketamir-2在一期临床试验中展现出良好的安全性与耐受性。该阶段试验结果显示,未出现任何严重不良事件或剂量限制性毒性,为后续临床开发奠定了重要基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.